Shira Dinner, MD

Trials

Studies that name Shira Dinner, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:27 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT05289687 · Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

  Eastern Cooperative Oncology Group · recruiting · T-cell Acute Lymphoblastic Leukemia · study chair
• Ph1
  NCT02861040 · Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

  Northwestern University · withdrawn · Recurrent Adult Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia · principal investigator
• Ph1
  NCT02819804 · Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  Northwestern University · terminated · B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 12:27 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Cancer Center Administration
  P30CA060553 · NCI · NORTHWESTERN UNIVERSITY · PI Aleksandar Zafirovski · fiscal years 2012 to 2026
  Named on NCT02861040, NCT02819804